Tenofovir versus entecavir on recurrence and mortality of hepatitis B virus-related hepatocellular carcinoma after curative therapy
Open Access
- 29 February 2024
- journal article
- research article
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 123 (8) , 891-898
Abstract
No abstract availableKeywords
Funding Information
- National Taiwan University Hospital
- Ministry of Health and Welfare
- National Science and Technology Council
This publication has 31 references indexed in Scilit:
- The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus–related hepatocellular carcinomaEuropean Journal of Internal Medicine, 2021
- Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen–Positive Chronic Hepatitis BJournal of Clinical and Experimental Hepatology, 2021
- Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical ResectionHepatology, 2020
- Immunomodulatory Mechanism of Acyclic Nucleoside Phosphates in Treatment of Hepatitis B Virus InfectionHepatology, 2019
- Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis BJAMA Oncology, 2019
- The use of propensity score methods with survival or time‐to‐event outcomes: reporting measures of effect similar to those used in randomized experimentsStatistics in Medicine, 2013
- Association Between Nucleoside Analogues and Risk of Hepatitis B Virus–Related Hepatocellular Carcinoma Recurrence Following Liver ResectionJAMA, 2012
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liverLangenbeck's Archives of Surgery, 2010
- Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinomaHepatology Research, 2003